CRM is trading at $254.10 (-3.1%) amid a mixed market session, likely tracking modest broader market weakness rather than a clear company-specific catalyst.

  • The decline contrasts with prior gains following positive Q3 FY26 results reported earlier this month.
  • Recent positive coverage highlighted significant Agentforce AI wins, including a major contract with AstraZeneca.
  • The stock maintains strong analyst consensus, with Buy ratings and price targets reaching up to $380.